Vimarsana
Biggest News Aggregation in the World

Page 25 - Ioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ioscience Today - Breaking & Trending Today

Gufic Biosciences launches India's first indigenous Botulinum Toxin injection Zarbot - Vimarsana News

Gufic Biosciences launches India's first indigenous Botulinum Toxin injection Zarbot

Developed and manufactured in collaboration with US-based Prime Bio

Lexaria Bioscience Corp.: Lexaria Receives First Granted Patent in Canada - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Receives First Granted Patent in Canada

KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its

Lexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels - Vimarsana News

Lexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels

KELOWNA, BC / ACCESSWIRE / December 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it

Avidity Biosciences Ups Public Offering Size - Vimarsana News

Avidity Biosciences Ups Public Offering Size

San Diego-based biopharmaceuticals company Avidity Biosciences said on Thursday that it has upsized its public offering, and will be offering up 12,000,000 shares of its common stock at a price to the p

Related Topics:
Avidity Biosciences
Hyundai Bioscience: Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm - Vimarsana News

Hyundai Bioscience: Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

Polytaxel, a novel pain-free anticancer drug, may not require break periodsA new standard of care, more convenient than docetaxel, is suggestedHyundai Bioscience to enter clinical trial on pancreatic